Terminally ill woman followed through with her decision to end her life
the ONA take:
A 29-year-old woman with a likely stage 4 glioblastoma ended her life by taking a fatal dose of barbiturates, prescribed by her doctors.
The controversial case drew international attention when the woman, Brittany Maynard, announced her intent to end her own life in an online video campaign launched on October 6. Maynard’s story, however, began months earlier. She was first told of her diagnosis in January. Maynard underwent surgery to remove as much of the tumor as possible, but the tumor grew back 2 months later and was larger. Her prognosis was grim.
She researched her treatment options, discussed them with her doctors, and made her decision to forgo chemotherapy and radiation and to end her own life. Maynard and her family moved to Oregon because the state’s Death with Dignity Act allows physicians to prescribe life-ending medication to certain terminally ill patients.
Although Maynard chose November 1 as the date she would end her life, she was open to pushing it back or forward depending on her condition and symptoms. In this account of her illness, Maynard explained how she made her decision and lived out the rest of her life, and the legacy her decision would leave. Currently, three states have Death with Dignity laws: Oregon, Washington, and Vermont.
Brittany Maynard ended her life by taking a fatal dose of barbiturates.
Brittany Maynard, who became the public face of the controversial right-to-die movement over the last few weeks, ended her own life Saturday at her home in Portland, Oregon. She was 29.
"Goodbye to all my dear friends and family that I love. Today is the day I have chosen to pass away with dignity in the face of my terminal illness, this terrible brain cancer that has taken so much from me … but would have taken so much more," she wrote on Facebook.
- FDA Grants Approval to Bevacizumab-awwb as First Biosimilar for Anticancer Therapy
- Efficacy of Octreotide LAR, Lanreotide in Management of Carcinoid Tumors
- Multivitamin Use May Reduce Risk of Chemo-Induced Neuropathy
- Overall Survival in Advanced Melanoma Improved With Nivolumab, Ipilimumab Combination
- Adjuvant Durvalumab Therapy May Prolong Progression-free Survival in NSCLC
- Invisible Burdens: The Complex Needs of Caregivers of Patients With Brain Cancer
- Cannabis Reduces Response Rate to Immunotherapy for Cancer
- Perioperative Blockade of Pathways May Improve Outcomes in Breast Cancer
- Zika Virus Preferentially Targets Glioblastoma Stem Cells
- Daratumumab Infusion-Related Reactions Managed by Pre/Postinfusion Medications
- Lorazepam Plus Haloperidol Improves Agitation in Cancer-Related Delirium
- Cost of Care Significantly Increased With Carcinoid Syndrome in NETs
- Treating Intractable Hiccups in Advanced Cancer, Palliative Care Setting
- Severe Mental Illness May Worsen Breast Cancer Survival Outcomes
- Imaging Management of Breast Density, a Controversial Risk Factor for Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|